Abstract

Personalized medicine is a progress in medicine with the treatment principles: "The right patients with the right drug, the right dose, and the right time". Personalized medicine involved identifying genetic, genomic and clinical manifestation that allowed accurate predictions of person that might develop disease, progressive disease, and their response to treatment.

There are many techniques: X-ray, ultrasound, CT scan, MRI, PET CT, cancer markers,... for diagnosis of cancer and of disease stages. The notion of "companion diagnostics", whereby molecular tests that measure levels of proteins, genes, or specific mutations are used for stratifying disease status, to predict disease development as well as to provide a highly specific therapy for an individual's cancer. Along with the targeting therapy, personalized medicine in cancer development is increasingly widespread.

There are many techniques, such as: ECG, biomarkers, intravascular ultrasound, CT scan...for diagnosis of cardiovascular disease and their stages. The detection of genome changing helps to diagnose the risk and prognosis. In the pharmacogenetic and pharmacogenomic domains, with the discovery of the gene mutations, simple nucleotide polymorphism (SNPs) and Copy- number variation (VNVs) of cardiovascular patients can get help to choose appropriate and effective medicines as well as appropriate therapeutic dose to avoid excessive effects of drugs.

Personalized medicine provides the means to predict, prevent, treat and cure diseases, it also enable prognostics, target therapy, promote longitudinal wellness and advance health care for the community.

Personalized medicine contributes to the evolution of health management practice, especially in cardiovascular diseases fields. In the future, it will affect the entire landscape of healthcare system.